Medicine & Life Sciences
Breast Neoplasms
100%
Triple Negative Breast Neoplasms
97%
Mutation
45%
Neoplasms
43%
Neoadjuvant Therapy
40%
Lasofoxifene
38%
5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine
37%
human ERBB2 protein
36%
palbociclib
31%
Tumor-Infiltrating Lymphocytes
27%
Progression-Free Survival
27%
Cyclin-Dependent Kinase 6
26%
Electrophoresis, Gel, Two-Dimensional
25%
Fibroblast Growth Factor Receptors
25%
Cyclin-Dependent Kinase 4
24%
Survival
23%
Hormones
22%
Proteomics
22%
Precision Medicine
21%
Circulating Tumor DNA
20%
Therapeutics
20%
mirvetuximab soravtansine
20%
Estrogen Receptors
20%
2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide
19%
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
18%
High-Throughput Nucleotide Sequencing
18%
selinexor
18%
talazoparib
18%
Proteins
17%
Immunoconjugates
16%
Radium-223
16%
Folate Receptor 1
16%
eribulin
16%
Mammary Paget's Disease
15%
atezolizumab
15%
130-nm albumin-bound paclitaxel
15%
sacituzumab govitecan
15%
Electrophoresis
13%
Clinical Trials
13%
Takotsubo Cardiomyopathy
13%
Gels
13%
Fulvestrant
13%
Tumor Burden
12%
Peptide Mapping
12%
Disease Progression
12%
Tensins
12%
Decitabine
12%
Catalogs
12%
Whole Exome Sequencing
12%
Nipples
11%